217 related articles for article (PubMed ID: 19422460)
1. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
[TBL] [Abstract][Full Text] [Related]
2. Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia.
Hardy AT; Palma-Barqueros V; Watson SK; Malcor JD; Eble JA; Gardiner EE; Blanco JE; Guijarro-Campillo R; Delgado JL; Lozano ML; Teruel-Montoya R; Vicente V; Watson SP; Rivera J; Ferrer-Marín F
Thromb Haemost; 2018 Jun; 118(6):1009-1020. PubMed ID: 29695020
[TBL] [Abstract][Full Text] [Related]
3. Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.
Manne BK; Badolia R; Dangelmaier C; Eble JA; Ellmeier W; Kahn M; Kunapuli SP
J Biol Chem; 2015 May; 290(18):11557-68. PubMed ID: 25767114
[TBL] [Abstract][Full Text] [Related]
4. Akt and mitogen-activated protein kinase enhance C-type lectin-like receptor 2-mediated platelet activation by inhibition of glycogen synthase kinase 3α/β.
Moroi AJ; Watson SP
J Thromb Haemost; 2015 Jun; 13(6):1139-50. PubMed ID: 25858425
[TBL] [Abstract][Full Text] [Related]
5. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.
Suzuki-Inoue K; Fuller GL; García A; Eble JA; Pöhlmann S; Inoue O; Gartner TK; Hughan SC; Pearce AC; Laing GD; Theakston RD; Schweighoffer E; Zitzmann N; Morita T; Tybulewicz VL; Ozaki Y; Watson SP
Blood; 2006 Jan; 107(2):542-9. PubMed ID: 16174766
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry.
Cheung HYF; Moran LA; Sickmann A; Heemskerk JWM; Garcia Á; Watson SP
Platelets; 2022 Nov; 33(8):1293-1300. PubMed ID: 35535424
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.
Zheng TJ; Lofurno ER; Melrose AR; Lakshmanan HHS; Pang J; Phillips KG; Fallon ME; Kohs TCL; Ngo ATP; Shatzel JJ; Hinds MT; McCarty OJT; Aslan JE
Am J Physiol Cell Physiol; 2021 May; 320(5):C902-C915. PubMed ID: 33689480
[TBL] [Abstract][Full Text] [Related]
8. C-type lectin-like receptor-2 (CLEC-2) is a key regulator of kappa-carrageenan-induced tail thrombosis model in mice.
Yokomori R; Shirai T; Tsukiji N; Oishi S; Sasaki T; Takano K; Suzuki-Inoue K
Platelets; 2023 Dec; 34(1):2281941. PubMed ID: 38010137
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine phosphorylation on spleen tyrosine kinase (Syk) is differentially regulated in human and murine platelets by protein kinase C isoforms.
Buitrago L; Bhavanasi D; Dangelmaier C; Manne BK; Badolia R; Borgognone A; Tsygankov AY; McKenzie SE; Kunapuli SP
J Biol Chem; 2013 Oct; 288(40):29160-9. PubMed ID: 23960082
[TBL] [Abstract][Full Text] [Related]
10. The N-terminal SH2 domain of Syk is required for (hem)ITAM, but not integrin, signaling in mouse platelets.
Hughes CE; Finney BA; Koentgen F; Lowe KL; Watson SP
Blood; 2015 Jan; 125(1):144-54. PubMed ID: 25352128
[TBL] [Abstract][Full Text] [Related]
11. G6b-B inhibits constitutive and agonist-induced signaling by glycoprotein VI and CLEC-2.
Mori J; Pearce AC; Spalton JC; Grygielska B; Eble JA; Tomlinson MG; Senis YA; Watson SP
J Biol Chem; 2008 Dec; 283(51):35419-27. PubMed ID: 18955485
[TBL] [Abstract][Full Text] [Related]
12. Micromolar concentrations of citalopram or escitalopram inhibit glycoprotein VI-mediated and integrin αIIbβ3-mediated signaling in human platelets.
Tseng YL; Braun A; Chang JP; Chiang ML; Tseng CY; Chen W
Toxicol Appl Pharmacol; 2019 Feb; 364():106-113. PubMed ID: 30592962
[TBL] [Abstract][Full Text] [Related]
13. CEACAM2 negatively regulates hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo.
Alshahrani MM; Yang E; Yip J; Ghanem SS; Abdallah SL; deAngelis AM; O'Malley CJ; Moheimani F; Najjar SM; Jackson DE
Blood; 2014 Oct; 124(15):2431-41. PubMed ID: 25085348
[TBL] [Abstract][Full Text] [Related]
14. ITAM receptor-mediated generation of reactive oxygen species in human platelets occurs via Syk-dependent and Syk-independent pathways.
Arthur JF; Qiao J; Shen Y; Davis AK; Dunne E; Berndt MC; Gardiner EE; Andrews RK
J Thromb Haemost; 2012 Jun; 10(6):1133-41. PubMed ID: 22489915
[TBL] [Abstract][Full Text] [Related]
15. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies.
Lhermusier T; van Rottem J; Garcia C; Xuereb JM; Ragab A; Martin V; Gratacap MP; Sié P; Payrastre B
J Thromb Haemost; 2011 Oct; 9(10):2067-76. PubMed ID: 21848694
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation on Syk Y342 is important for both ITAM and hemITAM signaling in platelets.
Kostyak JC; Mauri B; Dangelmaier C; Vari HR; Patel A; Wright M; Reddy H; Tsygankov AY; Kunapuli SP
J Biol Chem; 2022 Aug; 298(8):102189. PubMed ID: 35753354
[TBL] [Abstract][Full Text] [Related]
17. Novel interactions in platelet biology: CLEC-2/podoplanin and laminin/GPVI.
Ozaki Y; Suzuki-Inoue K; Inoue O
J Thromb Haemost; 2009 Jul; 7 Suppl 1():191-4. PubMed ID: 19630798
[TBL] [Abstract][Full Text] [Related]
18. G
Badolia R; Inamdar V; Manne BK; Dangelmaier C; Eble JA; Kunapuli SP
J Biol Chem; 2017 Sep; 292(35):14516-14531. PubMed ID: 28705934
[TBL] [Abstract][Full Text] [Related]
19. Critical role of Src-Syk-PLC{gamma}2 signaling in megakaryocyte migration and thrombopoiesis.
Mazharian A; Thomas SG; Dhanjal TS; Buckley CD; Watson SP
Blood; 2010 Aug; 116(5):793-800. PubMed ID: 20457868
[TBL] [Abstract][Full Text] [Related]
20. A critical role for the regulation of Syk from agglutination to aggregation in human platelets.
Shih CH; Chiang TB; Wang WJ
Biochem Biophys Res Commun; 2014 Jan; 443(2):580-5. PubMed ID: 24326074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
